BAVA:CPH
Bavarian Nordic A/S
DKKÂ 213.40
arrow_upward
+0.09%(+0.20) 1D
Aug 28, 5:00:00 PM GMT+2 · DKK
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BAVA...
Open
DKKÂ 215.20
High
DKKÂ 217.00
Low
DKKÂ 213.20
Mkt. cap
16.91B
Avg. vol.
194.04K
Volume
103.52K
52-wk high
DKKÂ 243.70
52-wk low
DKKÂ 171.30
Shares outstanding
79.24M
No. of employees
2K
Open
DKKÂ 215.20
High
DKKÂ 217.00
Low
DKKÂ 213.20
Mkt. cap
16.91B
Avg. vol.
194.04K
Volume
103.52K
52-wk high
DKKÂ 243.70
52-wk low
DKKÂ 171.30
Shares outstanding
79.24M
No. of employees
2K
News stories
From web sources and news partners
TipRanks
·
5 hours ago
Bavarian Nordic Earnings Call Signals Profitable Growth
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination. In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
About Bavarian Nordic A/S
CEOPaul Chaplin
Employees1.91K
FoundedJul 1, 1992
Headquarters-
SectorBiotechnology
Websitebavarian-nordic.com
AI content may include mistakes. Learn more